Wecomput Technology Co.

What Wecomput Technology Co. does

Wecomput Technology Co. (北京中大唯信科技有限公司, branded as 唯信计算 / Wecomput) is a privately held Chinese AI drug discovery software and services company founded in 2015 and headquartered in Beijing, with R&D centers in Shanghai and Guangzhou. Its core product, WeMol, is a molecular digital intelligent computing platform that integrates computational biology, AI-driven drug design, molecular simulation, and quantum chemistry into a flow-based, low-code architecture with over 200 computational modules spanning antibodies, proteins, small molecules, mRNA, nucleic acids, and biomaterials. The platform is complemented by sub-products including WeSeq (sequence editor), WeView (structure visualization), WeDraw (chemical structure editor), WeBox (molecular data management), and WeStation (GPU hardware/software integrated solutions), and embeds proprietary algorithms such as AlphaMHC for immunogenicity prediction.

The company operates a multi-revenue-stream model: SaaS subscriptions to WeMol Cloud (freemium tier plus paid plans) for enterprise and individual researchers, project-based computational services (virtual screening, molecular dynamics, antibody humanization, affinity maturation, quantum chemistry), paid in-person training under the WeMol Workshop (唯信工坊) brand priced at 1200–1800 RMB per participant, and bundled hardware sales of WeStation GPU workstations and servers. Notable proprietary AI capabilities include the AlphaMHC deep neural network for immunogenicity prediction (ROC-AUC 0.87, 80%+ accuracy, validated against FDA/EMA clinical data) and integration with protein language models (ESM-1b, ESM-1v) for antibody design.

Wecomput serves pharmaceutical and biotech companies, academic institutions, and research hospitals across the Hit-to-PCC pipeline. Publicly disclosed customers include Innovent Biologics, Hengrui Medicine, WuXi Biologics, LePU Bio, Hutchison China MediTech, PowerChain Biologics, 3S Biologics, Biointron, Jiangsu Yoyoubi Technology, GenSeat, and Shanghai Hybio Pharmaceutical, with a cumulative base of 500+ customers and 10,000+ registered users on WeMol Cloud. The company is a National High-Tech Enterprise, an NVIDIA Inception Senior Member, and received equity investment from Sequoia Capital China in 2021. GTM is hybrid: direct enterprise sales for platform deployments, self-serve SaaS via WeMol Cloud, and event-driven demand generation through conferences and the annual WeMol User Conference.

Name

Wecomput Technology Co.

Legal name

北京中大唯信科技有限公司

Website

https://wecomput.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Wecomput Technology Co. (唯信计算) is a Chinese AI drug discovery software and services company that sells the WeMol molecular computing platform, project-based computational services, training, and GPU workstations to pharmaceutical, biotech, and academic customers across the drug discovery pipeline.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• AI drug discovery
• Computational drug design
• Molecular dynamics simulation
• Antibody design software
• Biomedical AI platform

Headquarters

HQ city

Haidian

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. WeMol Software Platform (SaaS/Subscription): WeMol Cloud platform provided as SaaS subscription with tiered plans; WeMol also supports private cloud deployment. Core AI drug design software revenue stream.
2. Computational Services & Drug Design Projects: Project-based computational simulation and data analysis services including molecular docking, molecular dynamics, homology modeling, virtual screening, and AI-based drug design for pharmaceutical companies and research institutions. Thousands of projects delivered.
3. Training Courses (唯信工坊): In-person training courses on AI-assisted drug design (AIDD/CADD), priced at 1200 RMB per person for academic participants and 1800 RMB for enterprise, with group discounts available. Multiple sessions per year.
4. Hardware Solutions (WeStation): Integrated hardware and software solutions including GPU workstations/servers configured for molecular dynamics and other drug discovery computations, sold alongside software as bundled offerings.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Wecomput Technology Co. develops and operates the WeMol platform, a molecular digital intelligent computing platform for biopharmaceutical, materials and chemistry research. It integrates computational biology, AI, quantum chemistry and high-performance computing to support antibody design, small molecule design, nucleic acid design, molecular dynamics simulation, virtual screening, immunogenicity prediction, and protein structure prediction across the full Hit-to-PCC drug discovery pipeline. The company also delivers project-based computational services, hardware-software integrated solutions (WeStation), and training courses (WeMol Workshop).

Product overview

Wecomput offers a unified molecular digital intelligent computing platform ecosystem centered on WeMol, which integrates over 200 computational and AI modules for biopharmaceutical research. The platform portfolio includes WeMol (core AI drug design platform), WeSeq (sequence editor), WeView (structure visualization), WeDraw (chemical structure editor), WeBox (digital molecular management), and WeStation (hardware integration). Specialized algorithms like AlphaMHC for immunogenicity prediction are embedded within the platform. The platform supports the full drug discovery pipeline from Hit identification through Lead optimization to PCC selection, covering antibodies, proteins, nucleic acids, small molecules, and materials. WeMol Cloud provides browser-based access while WeStation offers hardware-software integrated solutions.

Differentiator

Problem solved

Functional benefit

Brands

• WeMol: 面向生物医药、材料、化学等领域的新一代分子数字化智能计算平台，集成计算生物学、AI、量子化学等模块，支持抗体、蛋白、小分子、核酸等分子设计与计算。
• WeStation
• WeDraw
• WeBox
• 唯信工坊

Products and services

• WeMol Platform (WeMol Cloud) Core molecular digital intelligent computing platform integrating computational biology, AI drug design, molecular simulation and quantum chemistry. Supports protein, antibody, nucleic acid, chemical drug, biomaterial and natural product design and modeling with 200+ computational modules across the full Hit-to-PCC pipeline. Delivered as a self-serve SaaS (WeMol Cloud) with optional private cloud deployment for enterprises.
• WeStation Hardware-Software Integrated Solution Integrated hardware and software solution bundling customized GPU workstations, servers and high-performance computing clusters with the WeMol software platform for biopharmaceutical customers needing on-premise molecular dynamics simulation and other drug discovery computations.
• WeDraw Chemical Structure Editor Standalone chemical structure editor for creating, editing and managing molecular structures with format conversion and export capabilities, used by medicinal chemists within the WeMol ecosystem.
• CADD/AIDD Computational Drug Design Services Project-based computational simulation and data analysis services including computer-aided drug design (CADD), AI-driven drug design (AIDD), molecular docking, molecular dynamics, homology modeling, virtual screening, antibody humanization, affinity maturation, developability assessment and immunogenicity prediction. Delivered to pharmaceutical companies and research institutions with thousands of projects completed.
• WeMol Workshop Training Courses (唯信工坊) In-person AIDD/CADD training courses teaching AI-assisted drug design using the WeMol platform. Multiple sessions per year in Shanghai, Beijing, Guangzhou and Jinan. Priced at 1200 RMB per person for academic participants and 1800 RMB for enterprise, with group discounts (20% off for 2, 30% off for 3+ participants); includes lunch, materials, WeMol Cloud account and complimentary compute credits.

Quantifiable outcome

• Antibody humanization completed in 2.5 weeks while retaining original affinity
• +8 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature11 records

Partnerships

Four partnerships are on record, tiered core and minor.

• NVIDIAcoreTechnology or Integration · 4 November 2024Featured in the NVIDIA/IDC generative AI white paper; WeMol platform completed end-to-end drug discovery coverage from small molecules to mRNA and protein design. WeMol integrated with NVIDIA BioNeMo platform. Company is a Senior Member of NVIDIA Inception Program.
• Innovent Biologics (信达生物)coreStrategic or Co-development Partner · 26 July 2024Strategic partnership to build and improve Innovent Biologics' Guoqing Academy computational platform using WeMol. WeMol will integrate with NVIDIA's BioNeMo platform to expand Innovent's AI computing capabilities. Goal is to build a high-efficiency, easy-to-use, digital, intelligent, automated one-stop AI drug R&D platform.
• Shandong University School of Pharmacy (山东大学药学院)minorStrategic or Co-development Partner · 17 October 2023Established industry-academia-research cooperation. Dr. Ge Hu (Class of 2005 graduate) appointed as 2023 external co-supervisor. WeMol platform used for teaching and research. Collaborative research projects ongoing.
• Shanghai University of Science and Technology (上海科技大学)minorStrategic or Co-development PartnerDr. Ge Hu serves as joint doctoral supervisor at ShanghaiTech University, facilitating academic collaboration and talent development.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Atomwise: San Francisco-based AI small-molecule discovery platform using 3D convolutional neural networks for virtual screening and lead optimization. Direct peer in AI-driven hit identification and virtual screening — the same use cases that anchor a significant share of WeMol's project services revenue.
• Insilico Medicine: Hong Kong/Shenzhen-based AI drug discovery company with end-to-end AIDD platform spanning target discovery, generative chemistry, and clinical-stage assets. Direct competitor for Chinese biopharma enterprise deals and academic collaborations in AIDD tooling.
• AbCellera: Vancouver-based antibody discovery platform combining single-cell sequencing, AI/ML screening, and a partnership-based business model with global pharma. Direct peer on the antibody side — WeMol's virtual affinity maturation, developability, and humanization capabilities compete with AbCellera's AI-driven antibody screening at tier-1 biopharma.
• BioMap: Beijing-based AI protein/biologics company building foundation models for protein design and partnering with Chinese biopharma. Direct peer in the Chinese AI biologics platform category, competing for similar academic and biopharma design partnerships across antibodies, enzymes, and de novo proteins.
• Hangzhou HiPiNova (Sphere Bio) / DP Technology: Beijing-based DP Technology offers the Bohrium molecular simulation platform alongside AI-driven drug design and materials science software — direct peer in the Chinese AIDD software platform category, comparable module breadth, and similar enterprise sales motion into Chinese pharma.
• XtalPi: Shenzhen-based AI drug discovery platform combining computational chemistry, quantum mechanics, and AI for small-molecule and biologics design. Closest direct competitor in the Chinese AIDD platform space, serving similar tier-1 Chinese biopharma customers and competing for the same enterprise platform budgets.

Emerging players

• BenchSci: Toronto-based AI platform for antibody and experiment design that uses NLP/ML to surface reagent and antibody data from literature. Emerging peer with overlap on antibody-related AI tooling for research scientists, though its depth is in reagent/experimental design rather than full drug-discovery pipelines.
• Generate Biomedicines: Flagship-founded generative biology company using ML to design de novo protein therapeutics. Emerging player with meaningful overlap on WeMol's antibody engineering, developability prediction, and de novo design ambitions, but operating from a US base with focused therapeutic-program economics rather than pure platform SaaS.
• Isomorphic Labs: Alphabet/DeepMind spinout applying AlphaFold-era foundation models to drug discovery with major pharma partnerships. Emerging direct competitor in AI-based structure prediction and generative chemistry, with vastly deeper R&D resources and a credible brand at global tier-1 pharma that could displace regional AIDD platforms.

Broad incumbents

• Schrödinger: US-listed computational chemistry and molecular simulation platform with established enterprise customer base among global pharma. Broad incumbent offering overlapping capabilities (molecular docking, FEP+, LiveDesign) to large pharma, but without WeMol's antibody/biologics depth or low-code flow architecture.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wecomput

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wecomput Technology Co.